USA—Philips has unveiled the clinical and economic advantages of its AI-powered cardiac monitoring solutions at the Heart Rhythm Annual Meeting in Boston.

The studies emphasized the pivotal role of mobile cardiac monitoring technology in enhancing early detection of adverse cardiac events, leading to potentially life-saving interventions while concurrently mitigating readmissions and reducing costs.

Cardiovascular diseases are escalating, compelling clinicians and health systems to seek efficient, cost-effective care delivery methods.

 Philips’ recent studies, spotlighted at the event, highlight the significance of mobile cardiac monitoring technology in revolutionizing patient care. 

One study, recently published in The Journal of Comparative Effectiveness Research, examined the outcomes of using Philips’ mobile cardiac outpatient telemetry (MCOT) wearable ECG sensor versus implantable loop recorders (ILRs) in stroke patients. 

Employing MCOT yielded notable benefits over an eighteen-month post-stroke period. Patients monitored with MCOT experienced significantly reduced readmissions compared to those observed with ILRs.

 Utilizing MCOT significantly decreased the average cost over the 18 months following the stroke event.

Instances of emergency department visits were notably lower among MCOT-monitored patients. 

Patients with complications and comorbidities from the index stroke exhibited a higher rate of survival when monitored with MCOT.

Manish Wadhwa, Chief Medical Officer for Philips Ambulatory Monitoring & Diagnostics, emphasized the critical role of high-quality data in effective cardiac monitoring. 

He highlighted how the AI-powered data platform behind MCOT empowers care teams to make informed decisions promptly, significantly impacting patient outcomes.

The significance of these findings prompted Philips to organize a moderated discussion on the comparative outcomes and cost analysis of ILR and MCOT following stroke, led by electrophysiologist Dr. Mohammad-Ali Jazayeri.

Moreover, two poster presentations delved into additional research, shedding light on Philips’ contributions to improved health outcomes and AI-driven diagnosis. 

One study showcased the potential of AI-powered ECG biomarker technology in identifying patients with significant intermittent bradyarrhythmia. 

Dr. Laurent Fiorina, a medical advisor for Philips, expressed their commitment to developing new AI models to detect cardiovascular conditions, thereby revolutionizing cardiac care.

Another study, the EP-COT Trial, examined the impact of Emergent Physician Notifications from MCOT on patient outcomes. 

The trial findings revealed MCOT’s effectiveness in detecting actionable arrhythmias and facilitating timely interventions by care teams.

Philips also prioritizes educating healthcare professionals on cardiac implantable electronic device (CIED) infections. 

Through Lead Management solutions, Philips equips physicians with tools for safe and predictable treatment, aiming to improve patient care quality.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook